ERBB2 and non-small cell lung carcinoma: Despite this, the findings from the DESTINY-Lung01 and DESTINY-Lung02 studies suggest that patients with stable BM experience systemic ORR and PFS that is similar to the cohort-at-large, and that the additional toxicity seen with the 6.4 mg/kg dose does not add additional therapeutic activity beyond what was observed with 5.4 mg/kg in both HER2-mutant and overexpressing NSCLC.